Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2017 March;59(1) > Panminerva Medica 2017 March;59(1):90-6



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Panminerva Medica 2017 March;59(1):90-6

DOI: 10.23736/S0031-0808.16.03201-8


language: English

Applications of cardiotoxicity in breast cancer: a meta-analysis

Hossein RAHMANI 1, Alireza SHAHRIARY 2, Mohammad A. SHEIKHI 3, Ahmad EBADI 4, Hannaneh DAVOODZADEH 5

1 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; 2 Laboratory of Proteomics, Chemical Injuries Research Center, and Department of Physiology and Biophysics, Baqiyatallah University of Medical Sciences, Tehran, Iran; 3 Department of Cardiac Surgery, Atherosclerosis Research Center, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 4 Department of Cardiac Anesthesiology, Golestan Hospital, Atherosclerosis Research Center, Pain Research Center, Ahvaz Jundishapur University, Ahvaz, Iran; 5 Department of Anesthesiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran


INTRODUCTION: Breast cancer is the most common type of cancer in women. Many antineoplastic agents used to treat breast cancer have potentially cardiotoxic effects and may lead to chemotherapy induced cardiomyopathy and heart failure. We conducted a meta-analysis to clarify the applications of cardiotoxicity in breast cancer.
EVIDENCE ACQUISITION: A published literature search was performed through PubMed, Cochrane Library, Medline, and Science Citation Index Expanded databases for articles published in English. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using random or fixed effects models. Heterogeneity was assessed using χ2 and I2 statistics. We performed a formal meta-analysis using summary measures from these studies.
EVIDENCE SYNTHESIS: In total, 9 published studies were included in the final analysis. The combined analysis revealed that there was non-significant regardless of the statistical ejection fraction (OR=0.98, 95% CI: 0.63-1.54, P=0.96) and left ventricular ejection fraction (OR=1.04; 95% CI: 0.69-1.56, P=0.85) decline method used. Additionally, the pooled OR was 0.99 (95% CI: 0.79-1.28) for the trastuzumab plus lapatinib combination, and 1.00 (95% CI: 0.88-1.13) for the trastuzumab plus pertuzumab combination.
CONCLUSIONS: In this meta-analysis, there was evidence indicated that there was not a significant decrease on LVEF and EF in patients who received trastuzumab plus lapatinib and trastuzumab plus pertuzumab combination. Our study suggests that the combination of two anti-HER2 agents does not significantly increase the risk for adverse compared with anti-HER2 monotherapy in patients with adequate cardiac function prior to start of therapy.

KEY WORDS: Cardiotoxicity - Breast neoplasms - Meta-analysis

top of page